DBV Technologies S.A. - Spons-ADR
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Find out what a historical investment in DBV Technologies S.A. - Spons-ADR would be worth today using our DBVT stock calculator.
$300.90M
-
0.00%
64.47K
$11.30
$10.48
$10.65
$12.78
$2.20
Ready to start your investing journey with Stake?
Open an accountDBVT FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in DBVT
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in DBVT
on Stake
Buy DBVT from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of DBVT from only US$10 with fractional shares
